Immunoassay Drug Testing: Principles and Limitations

Immunoassay drug testing is a screening method that uses antibodies to detect the presence of drugs or their metabolites in biological samples such as urine, blood, or oral fluid. These tests are widely used in clinical laboratories, emergency departments, pain management clinics, and workplace testing programs because they are rapid, inexpensive, and easy to perform. However, immunoassays are qualitative screening tools that produce presumptive results, and they are subject to false positives from cross-reacting substances and false negatives from drugs that the assay does not detect. Confirmatory testing using a second independent chemical technique such as gas chromatography with mass spectrometry is required before a positive screening result can be considered definitive. This article explains how immunoassays work, their practical applications, their known limitations, and how laboratory professionals should interpret results and decide when to request confirmation.

Laboratory students, technicians, researchers, and diagnostic professionals need to understand both the utility and the boundaries of immunoassay technology. The practical outcome of this article is a checklist for interpreting immunoassay drug test results and determining when confirmatory testing is necessary. The content draws on peer-reviewed literature, official guidance documents, and manufacturer data to provide evidence-based direction for clinical and forensic decision making.

At a Glance

Immunoassay drug testing occupies a specific role in the diagnostic workflow. It is a screening step, not a diagnostic endpoint. The table below summarizes the key characteristics that laboratory professionals must consider when using these assays.

The distinction between screening and confirmation is the foundation of safe immunoassay use. A positive immunoassay result should never be the sole basis for a clinical decision that affects patient care, legal status, or employment. The World Health Organization Laboratory Quality Management System Handbook emphasizes that quality management in laboratory testing requires understanding the limitations of each method and implementing appropriate quality control measures. Similarly, the FDA Bioanalytical Method Validation Guidance provides expectations for demonstrating that an analytical method is suitable for its intended use, which includes characterizing specificity and selectivity.

Core Principles of Immunoassay Technology

Immunoassays exploit the specific binding between an antibody and its target antigen. In drug testing, the target antigen is a drug molecule or one of its metabolites. The assay measures the extent of this binding reaction to indicate whether the drug is present in the sample above a defined cutoff concentration.

Antibody-Antigen Binding

Antibodies used in drug testing immunoassays are selected for their ability to recognize a specific drug or drug class. The binding is based on molecular recognition, meaning the antibody binds to a particular structural region of the drug molecule. This structural recognition is the source of both the utility and the limitation of immunoassays. A drug that shares structural similarity with the target can also bind to the antibody, producing a positive signal even when the target drug is absent. The National Center for Advancing Translational Sciences Assay Guidance Manual describes the principles of assay development and the importance of understanding antibody specificity when designing and interpreting immunoassays.

Competitive Binding Formats

Most drug testing immunoassays use a competitive binding format. In this design, the drug in the patient sample competes with a labeled drug reagent for a limited number of antibody binding sites. When the patient sample contains the drug, it displaces or prevents the labeled drug from binding to the antibody, and the measured signal is inversely proportional to the drug concentration. Higher drug concentrations produce lower signals in competitive assays.

Common formats include enzyme immunoassay, enzyme multiplied immunoassay technique, cloned enzyme donor immunoassay, and fluorescence polarization immunoassay. Each format uses a different detection mechanism, but all rely on the same fundamental antibody-antigen competition. Lateral flow immunoassays, commonly known as test strips, use a similar principle in a portable format and are frequently used for drug checking applications in community settings.

Cutoff Concentrations

Immunoassay results are interpreted against a cutoff concentration. The cutoff is the drug concentration above which the test is considered positive and below which it is considered negative. Cutoffs are established by manufacturers and validated for specific sample types. They are chosen to balance sensitivity and specificity, minimizing both false positives and false negatives. A sample with a drug concentration near the cutoff may produce inconsistent results due to normal assay variability, which is why results near the cutoff require careful interpretation and often confirmatory testing.

Practical Workflow for Immunoassay Drug Testing

Implementing immunoassay drug testing in a laboratory or point-of-care setting requires a structured workflow that includes specimen collection, handling, analysis, result interpretation, and documentation. Each step affects the reliability of the final result.

Specimen Collection and Handling

Urine is the most common specimen for drug testing immunoassays because drugs and their metabolites are concentrated in urine and the sample is easy to collect. However, urine samples can be adulterated, substituted, or diluted by individuals attempting to mask drug use. The American Family Physician review on urine drug tests notes that urine samples can be adulterated with other substances to mask positive results, and laboratory professionals must be familiar with these substances, the methods to detect them, and their effects on urine drug testing.

Specimen integrity checks should include temperature measurement within four minutes of collection, pH testing, creatinine concentration, and specific gravity. Any sample that falls outside expected ranges should be flagged for potential adulteration. Collection procedures should minimize opportunities for tampering, and chain of custody documentation is required when results may be used for legal or employment decisions.

Quality Control Procedures

Quality control is essential for reliable immunoassay results. The World Health Organization Laboratory Quality Management System Handbook provides a framework for implementing quality control in laboratory settings. Each batch of immunoassay tests should include positive and negative controls. Positive controls verify that the assay can detect the target drug at or above the cutoff. Negative controls verify that the assay does not produce a positive signal in the absence of the drug. Control results must fall within the manufacturer's specified ranges before patient results can be reported.

Calibration of automated immunoassay analyzers should be performed according to the manufacturer's recommendations and after any major maintenance or reagent lot change. Quality control data should be recorded and reviewed regularly to identify trends that may indicate reagent degradation, instrument malfunction, or operator error.

Running the Assay

The specific steps for running an immunoassay depend on the platform. Automated analyzers require loading reagents, calibrators, controls, and patient samples according to the instrument protocol. Point-of-care tests require following the manufacturer's instructions precisely, including correct sample volume, timing, and reading of results. Lateral flow test strips require dipping the strip into the sample for the specified duration and reading the result within the specified window. Reading a lateral flow test too early or too late can produce incorrect results.

Recording and Reporting Results

All immunoassay results should be recorded with the date, time, operator, reagent lot number, control results, and any observations about the sample or the testing process. Results should be reported as presumptive positive or negative, with a clear statement that positive results require confirmation by a second independent method. The reporting system should flag results that are near the cutoff or that are inconsistent with the clinical presentation.

Options and Tradeoffs in Immunoassay Selection

Laboratory professionals must choose among different immunoassay platforms and reagents. The selection affects the drugs that can be detected, the cross-reactivity profile, and the operational characteristics of the testing program.

Drug Classes and Assay Panels

Immunoassays are available for many drug classes, including amphetamines, opiates, benzodiazepines, cannabinoids, cocaine, phencyclidine, tricyclic antidepressants, and barbiturates. Some assays detect a single drug, while others detect a class of structurally related drugs. Class-specific assays are useful for broad screening but have more complex cross-reactivity profiles because they must recognize multiple related compounds.

The Journal of Analytical Toxicology review of false-positive interferences in urine drug screen immunoassays describes false-positive results for amphetamines, opiates, benzodiazepines, cannabinoids, tricyclic antidepressants, phencyclidine, lysergic acid diethylamide, and barbiturates. This review supports the generally accepted practice that immunoassay positive results are considered presumptive until confirmed by a second independent chemical technique.

Platform Considerations

Automated analyzers offer high throughput, built-in quality control features, and electronic result recording. They require significant capital investment, regular maintenance, and trained operators. Point-of-care tests offer portability and rapid results but may have less rigorous quality control and more variability in operator performance. Lateral flow test strips are inexpensive and simple but provide only qualitative results and may have limited sensitivity and specificity compared to laboratory-based methods.

A study of xylazine lateral flow immunoassay test strips for drug checking applications found that the strips consistently detected xylazine at concentrations above 2.5 micrograms per milliliter and demonstrated high sensitivity and specificity when compared to mass spectrometry results. However, the study also found cross-reactivity with lidocaine, a common cutting agent, and no reactivity with other alpha-2 agonists found in the illicit drug supply. This finding highlights the need to offer comprehensive drug checking services that identify a range of substances.

Manufacturer Cross-Reactivity Data

Manufacturer package inserts provide cross-reactivity data that describe how the assay responds to compounds other than the target drug. However, a study in Academic Pathology found wide variability in how manufacturer cross-reactivity data are summarized in package inserts for commercially available amphetamines, benzodiazepines, and opiates immunoassays. The study found variability in the number of compounds tested, the manner in which cross-reactivity is measured, the concentration units used, and the availability of package inserts online. Cross-reactivity data were sparse with respect to off-target drugs known to be cross-reactive and designer drugs.

Laboratory professionals should review package inserts for the specific assays they use and maintain a reference file of known cross-reactants. However, the absence of a compound from the package insert does not guarantee that the compound will not cross-react. The package insert data are based on the manufacturer's testing, which may not include every possible interfering substance.

Observations and Measurements in Immunoassay Testing

Interpreting immunoassay results requires understanding the relationship between the measured signal and the drug concentration, as well as the factors that can distort this relationship.

Signal Interpretation

In competitive immunoassays, the signal decreases as drug concentration increases. The assay software or the operator converts the signal to a qualitative result by comparing it to the cutoff calibrator. Some assays provide semi-quantitative results that estimate the drug concentration relative to the calibration curve. Semi-quantitative results can be useful for clinical interpretation but should not be treated as precise measurements.

Cross-Reactivity Measurement

Cross-reactivity is typically expressed as the concentration of the cross-reacting compound that produces a signal equivalent to a given concentration of the target drug. A compound with high cross-reactivity produces a positive result at a low concentration, while a compound with low cross-reactivity requires a high concentration to produce a positive result. The Clinical Chemistry study on discovering cross-reactivity through electronic health records analysis quantified potential cross-reactivity as an odds ratio from logistic regression and validated findings experimentally by spiking ingredients into drug-free urine. This study discovered previously unknown cross-reactivities affecting assays for amphetamines, buprenorphine, cannabinoids, and methadone.

Limit of Detection and Sensitivity

The limit of detection is the lowest drug concentration that the assay can distinguish from a negative sample. Sensitivity is the proportion of true positive samples that the assay correctly identifies as positive. A study of xylazine lateral flow immunoassays reported a sensitivity of 0.974, specificity of 1.00, and overall accuracy of 0.986 when compared to gas chromatography tandem mass spectrometry results. These performance characteristics are specific to that particular test and cannot be generalized to all immunoassays.

Records and Documentation Requirements

Accurate documentation is essential for immunoassay drug testing, particularly when results may be used for clinical decisions, legal proceedings, or employment determinations.

Chain of Custody

Chain of custody documentation tracks the specimen from collection through analysis to result reporting. Each person who handles the specimen must be identified, and each transfer must be documented. Chain of custody is required for forensic drug testing and is recommended for any testing where the result may be disputed.

Quality Control Records

Quality control records should include the date and time of each control test, the control lot numbers, the expected and observed results, and the operator's identity. These records provide evidence that the assay was performing correctly when patient samples were tested. The World Health Organization Laboratory Quality Management System Handbook emphasizes the importance of documentation in demonstrating the reliability of laboratory results.

Result Reporting

The result report should include the patient or sample identifier, the specimen type, the drugs tested, the assay method, the cutoff concentration, the qualitative result, and a statement that positive results are presumptive and require confirmation. The report should also include any relevant observations about specimen integrity or assay performance.

Quality Controls and Assurance Measures

Quality assurance in immunoassay drug testing extends beyond running controls with each batch. It includes ongoing monitoring of assay performance, participation in external quality assessment programs, and regular review of testing procedures.

Internal Quality Control

Internal quality control involves running control samples with known drug concentrations alongside patient samples. Controls should include samples at the cutoff concentration, samples above the cutoff, and negative samples. The frequency of control testing depends on the assay volume and the manufacturer's recommendations. Control results should be plotted on Levey-Jennings charts to identify trends or shifts in assay performance.

External Quality Assessment

External quality assessment programs provide blinded samples that laboratories test and report to a central agency. The agency compares the laboratory's results to those of other laboratories and to the expected results. Participation in external quality assessment programs helps laboratories identify systematic errors and compare their performance to peers.

Proficiency Testing

Proficiency testing is a form of external quality assessment that evaluates the laboratory's ability to produce accurate results. Laboratories that participate in proficiency testing receive samples with known drug concentrations and must report results within specified tolerances. Poor proficiency testing performance requires investigation and corrective action.

Common Failure Patterns and Troubleshooting

Laboratory professionals should be familiar with the common ways that immunoassay drug testing can fail. Recognizing these patterns allows for prompt investigation and correction.

False Positive Results

False positives occur when the assay produces a positive result in a sample that does not contain the target drug. The most common cause is cross-reactivity with a structurally similar compound. The Journal of Analytical Toxicology review of false-positive interferences describes cross-reactivities with many analytes that can cause false-positive results in initial drug screens. Knowledge of these potential interferents is important in determining a course of action for patient care.

Common cross-reactants include over-the-counter cold medications that contain sympathomimetic amines, which can cross-react with amphetamine assays. Some antibiotics, antipsychotics, and antihistamines have been reported to cross-react with various drug class assays. The review in Clinical Chemistry identified previously unknown cross-reactivities affecting assays for amphetamines, buprenorphine, cannabinoids, and methadone through large-scale analysis of electronic health records.

False Negative Results

False negatives occur when the assay produces a negative result in a sample that contains the target drug. This can happen when the drug is present at a concentration below the cutoff, when the assay does not detect the specific drug or metabolite present, or when the sample has been adulterated or diluted.

The American Family Physician review notes that immunoassays for opioids may not detect commonly prescribed semisynthetic and synthetic opioids such as methadone and fentanyl. Similarly, immunoassays for benzodiazepines may not detect alprazolam or clonazepam. These limitations mean that a negative immunoassay result does not exclude drug use, particularly when the patient may be taking a drug that the assay does not detect.

Adulteration and Sample Manipulation

Individuals may attempt to adulterate urine samples to produce false negative results. Common adulterants include bleach, vinegar, soap, and commercial adulterant products. Adulterants can interfere with the antibody-antigen reaction or degrade the drug in the sample. Specimen integrity testing should detect most adulteration attempts. The American Family Physician review emphasizes that family physicians must be familiar with these substances, the methods to detect them, and their effects on urine drug testing.

Near-Cutoff Results

Samples with drug concentrations near the cutoff can produce inconsistent results due to normal assay variability. A sample that tests positive on one run may test negative on a repeat run. Near-cutoff results should be interpreted with caution and should generally be confirmed by a second method.

Limitations of Immunoassay Drug Testing

The limitations of immunoassay drug testing are well documented in the peer-reviewed literature. Understanding these limitations is essential for appropriate test interpretation.

Presumptive Nature of Results

The most important limitation is that immunoassay results are presumptive, not definitive. The Journal of Analytical Toxicology review states that false-positive results support the generally accepted practice that immunoassay positive results are considered presumptive until confirmed by a second independent chemical technique. The American Family Physician review similarly states that immunoassays can give false-positive and false-negative results, so all results are considered presumptive until confirmatory testing is performed.

Limited Drug Detection

Immunoassays detect only the drugs and drug classes that the specific assay is designed to recognize. Designer drugs that share structural similarities to amphetamines and phencyclidine have the potential to cross-react with assays designed to detect these compounds, but many designer drugs produce negative results on all commercially available immunoassays. A study in the Journal of Analytical Toxicology evaluated the cross-reactivity of five commercial immunoassay reagent kits for 94 designer drugs and found that 14 percent of the designer drugs produced a negative response for all five kits. No designer drug used in the study generated a positive result for all five immunoassay kits.

Cross-Reactivity Uncertainty

Manufacturer cross-reactivity data are incomplete and inconsistent. The Academic Pathology study found wide variability in how manufacturer cross-reactivity data are summarized in package inserts, with sparse data on off-target drugs and designer drugs. This lack of consistency complicates the interpretation of urine drug testing results. Laboratory professionals cannot assume that a compound not listed in the package insert will not cross-react.

Qualitative Nature

Most immunoassays provide qualitative results that indicate whether the drug is present above the cutoff concentration. They do not provide accurate quantitative measurements of drug concentration. The relationship between the immunoassay signal and the drug concentration is not linear across the full range, and semi-quantitative results should be interpreted with caution.

Safety and Regulatory Context

Immunoassay drug testing involves handling biological specimens that may contain infectious agents. Laboratory professionals must follow appropriate biosafety procedures to protect themselves and others from exposure.

Biosafety Considerations

The World Health Organization Laboratory Biosafety Manual provides guidance for safe handling of biological specimens in laboratory settings. Urine samples are generally considered low risk for bloodborne pathogen transmission, but they may contain other infectious agents. Standard precautions should be followed, including wearing gloves and laboratory coats, washing hands after handling specimens, and disinfecting work surfaces. Specimens should be transported and stored in leak-proof containers.

Regulatory Requirements

Laboratories that perform drug testing for clinical or forensic purposes must comply with applicable regulations. In the United States, laboratories that test for federally regulated workplace drug testing programs must be certified by the Substance Abuse and Mental Health Services Administration. Clinical laboratories must comply with the Clinical Laboratory Improvement Amendments. The FDA Bioanalytical Method Validation Guidance provides expectations for demonstrating that analytical methods are suitable for their intended use, which includes characterizing specificity, selectivity, and other performance parameters.

Professional Escalation Criteria

Laboratory professionals should escalate results to the ordering clinician or to a medical review officer when certain conditions are present. These conditions include positive immunoassay results that are inconsistent with the clinical presentation, positive results that may be explained by a cross-reacting medication, near-cutoff results that could affect clinical decisions, and any indication of specimen adulteration or substitution.

A study in the Journal of the American College of Emergency Physicians Open examined pediatric patients with positive amphetamine screens and found that false-positive methamphetamine results on rapid urine drug screens were common. Tachycardia and concurrent amphetamine positivity were strongly associated with confirmed methamphetamine exposure. The study concluded that clinicians should be aware of the limitations of immunoassay-based screening and consider confirmatory testing when the clinical picture is unclear.

Checklist for Interpreting Immunoassay Drug Test Results

The following checklist provides a structured approach to interpreting immunoassay drug test results and deciding when to request confirmatory testing.

Step 1: Verify Specimen Integrity

Confirm that the specimen was collected according to protocol and that chain of custody documentation is complete. Check specimen temperature, pH, creatinine, and specific gravity. Flag any sample that falls outside expected ranges for adulteration testing.

Step 2: Review Quality Control Results

Verify that positive and negative controls were run with the batch and that control results were within the manufacturer's specified ranges. Review quality control charts for trends or shifts that might indicate assay problems.

Step 3: Confirm the Assay and Cutoff

Identify the specific assay used, the drug class detected, and the cutoff concentration. Review the package insert for known cross-reactants and for drugs that the assay does not detect.

Step 4: Interpret the Result in Clinical Context

Consider the patient's medication list, clinical presentation, and reason for testing. A positive result that is consistent with the clinical picture is more likely to be a true positive. A positive result that is inconsistent with the clinical picture or that could be explained by a cross-reacting medication requires confirmation.

Step 5: Assess the Need for Confirmatory Testing

Request confirmatory testing when any of the following conditions apply: the result is positive and will be used for a clinical decision that affects treatment, the result is positive and inconsistent with the clinical presentation, the result is positive and could be explained by a cross-reacting medication, the result is near the cutoff, or the result is disputed by the patient.

Step 6: Document the Interpretation

Record the interpretation and the rationale for any decisions about confirmatory testing. Include the assay method, cutoff, control results, specimen integrity findings, and the clinical context in the documentation.

Step 7: Communicate Results Clearly

Report results as presumptive positive or negative. Clearly state that positive results require confirmation. Communicate any concerns about specimen integrity or assay performance to the ordering clinician.

Common Failure Patterns in Result Interpretation

Several recurring errors in immunoassay result interpretation have been identified in the literature. Recognizing these patterns can help laboratory professionals avoid them.

Treating Presumptive Results as Definitive

The most common error is treating a positive immunoassay result as a definitive finding. The peer-reviewed literature consistently emphasizes that immunoassay results are presumptive until confirmed by a second independent chemical technique. A positive immunoassay result should trigger confirmatory testing, not a final clinical or legal decision.

Ignoring Cross-Reactivity Possibilities

Laboratory professionals and clinicians may fail to consider cross-reactivity when interpreting positive results. The Clinical Chemistry study on electronic health records analysis found that exposure to a cross-reactive ingredient increased the odds of a false-positive screen. Reviewing the patient's medication list for known cross-reactants is an essential step in result interpretation.

Assuming Negative Results Exclude Drug Use

A negative immunoassay result does not exclude drug use. The assay may not detect the specific drug or metabolite present, or the drug may be present below the cutoff concentration. The American Family Physician review notes that immunoassays for opioids may not detect methadone and fentanyl, and immunoassays for benzodiazepines may not detect alprazolam or clonazepam.

Overlooking Specimen Adulteration

Failure to check specimen integrity can lead to false negative results from adulterated samples. Specimen integrity testing should be a routine part of the testing workflow, particularly when results may be used for legal or employment decisions.

Professional Escalation Criteria

Laboratory professionals should know when to escalate results to a higher level of review. The following situations warrant escalation to the ordering clinician, a medical review officer, or a laboratory director.

Positive Results with Clinical Consequences

Any positive result that could affect a patient's treatment plan, pain management agreement, employment status, or legal situation should be confirmed before action is taken. The American Family Physician review notes that false-positive results have important implications for a patient's pain treatment plan.

Positive Results Inconsistent with Clinical Presentation

A positive result that is inconsistent with the patient's reported medication use or clinical presentation should be investigated. The pediatric study on methamphetamine exposures found that false-positive results on rapid urine drug screens were common and that clinical factors such as tachycardia and concurrent amphetamine positivity were associated with confirmed exposure.

Suspected Specimen Adulteration

Any indication of specimen adulteration, substitution, or dilution should be escalated. The laboratory should document the findings and notify the ordering clinician. A confirmed adulterated specimen may require recollection under direct observation.

Near-Cutoff Results

Results that fall near the cutoff concentration should be flagged for confirmatory testing. The inherent variability of immunoassays means that near-cutoff results may not be reproducible on repeat testing.

Disputed Results

If the patient disputes a positive result, confirmatory testing should be performed. The confirmatory method should be sufficiently specific to provide a conclusive result.

Frequently Asked Questions

What does an immunoassay drug test measure?

An immunoassay drug test measures the presence of a drug or its metabolite in a biological sample by detecting the binding between an antibody and the drug molecule. The test produces a qualitative result that indicates whether the drug is present above a defined cutoff concentration. The result is presumptive and requires confirmation by a second independent method before it can be considered definitive.

How do immunoassays detect drugs of abuse?

Immunoassays use antibodies that recognize specific structural regions of drug molecules. In a competitive format, the drug in the patient sample competes with a labeled drug reagent for a limited number of antibody binding sites. The measured signal is inversely proportional to the drug concentration. Higher drug concentrations produce lower signals in competitive assays.

What causes false-positive results in immunoassay drug testing?

False-positive results are most commonly caused by cross-reactivity, which occurs when a compound other than the target drug binds to the antibody and produces a positive signal. Many medications and over-the-counter products can cross-react with drug class immunoassays. The Journal of Analytical Toxicology review describes false-positive results for amphetamines, opiates, benzodiazepines, cannabinoids, tricyclic antidepressants, phencyclidine, lysergic acid diethylamide, and barbiturates.

What causes false-negative results in immunoassay drug testing?

False-negative results occur when the assay fails to detect a drug that is present in the sample. This can happen when the drug is present below the cutoff concentration, when the assay does not detect the specific drug or metabolite present, or when the sample has been adulterated or diluted. The American Family Physician review notes that immunoassays for opioids may not detect methadone and fentanyl, and immunoassays for benzodiazepines may not detect alprazolam or clonazepam.

When should confirmatory testing be requested?

Confirmatory testing should be requested when a positive result will be used for a clinical decision that affects treatment, when the result is inconsistent with the clinical presentation, when the result could be explained by a cross-reacting medication, when the result is near the cutoff, or when the result is disputed. Confirmatory testing uses a second independent chemical technique such as gas chromatography with mass spectrometry.

What is cross-reactivity in immunoassay testing?

Cross-reactivity is the response of an immunoassay to compounds other than the target drug. A compound with high cross-reactivity produces a positive result at a low concentration, while a compound with low cross-reactivity requires a high concentration to produce a positive result. Manufacturer package inserts provide cross-reactivity data, but this information is often incomplete and inconsistent across manufacturers.

Can designer drugs be detected by immunoassays?

Some designer drugs that share structural similarities to amphetamines and phencyclidine can cross-react with assays designed to detect these compounds. However, a study of 94 designer drugs found that 14 percent produced a negative response on all five commercial immunoassay kits tested, and no designer drug generated a positive result on all five kits. Confirmatory testing is essential for detecting designer drugs that immunoassays miss.

How should near-cutoff results be interpreted?

Near-cutoff results should be interpreted with caution because immunoassays have inherent variability. A sample with a drug concentration near the cutoff may produce inconsistent results on repeat testing. Near-cutoff results should generally be confirmed by a second method before any clinical or legal action is taken.

Related Diagnostic Guides

• Calibration Test: Performing and Interpreting Routine Checks on Lab Instruments
• How to Interpret a Citrate Utilization Test: Simmons Citrate Agar Protocol and Results
• Protein Immunoprecipitation: Principles and Protocol
• 2D Gel Electrophoresis: Principles and Workflow for Proteomics
• Calibration Report: How to Document and Interpret Calibration Results

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Sulfonamide Hypersensitivity: Fact and Fiction.. The journal of allergy and clinical immunology. In practice, 2019.
• False-positive interferences of common urine drug screen immunoassays: a review.. Journal of analytical toxicology, 2014.
• Urine Drug Tests: Ordering and Interpreting Results.. American family physician, 2019.
• IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper.. The World Allergy Organization journal, 2020.
• Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized.. The journal of allergy and clinical immunology. In practice, 2019.
• Determination of designer drug cross-reactivity on five commercial immunoassay screening kits.. Journal of analytical toxicology, 2015.
• Understanding sensitivity and cross-reactivity of xylazine lateral flow immunoassay test strips for drug checking applications.. Drug testing and analysis, 2024.
• Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records.. Clinical chemistry, 2019.
• Toxicology Testing: Interpreting What That Number Means.. 2026.
• Tachycardia and Positive Amphetamine Screen are Associated With True Positive-Methamphetamine Exposures in Pediatric Patients.. 2026.
• Is urinary toxicology rapid screening a useful first-line diagnostic tool for paediatric coma in the emergency department?. 2026.
• Congenital Adrenal Hyperplasia in the Mediterranean: A Concise Overview.. 2026.
• Screening of hepatitis C virus in dried plasma spots among people who inject drugs and attending syringe exchange programme in Delhi, India.. 2026.
• A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing. Academic Pathology, 2018.
• Accidental intoxications in toddlers: Lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays. BMC Clinical Pathology, 2019.
• Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays. Journal of Cheminformatics, 2014.
• Cross-reactivity of steroid hormone immunoassays: Clinical significance and two-dimensional molecular similarity prediction. BMC Clinical Pathology, 2014.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.